220 related articles for article (PubMed ID: 27114459)
1. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells.
Wang X; Haylock D; Hu CS; Kowalczyk W; Jiang T; Qiu J; Mosoyan G; He W; Marshall N; Mascarenhas J; Tarasova A; Brody J; Winkler D; Hoffman R
Blood; 2016 Jun; 127(26):3398-409. PubMed ID: 27114459
[TBL] [Abstract][Full Text] [Related]
2. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.
Wang X; Hu CS; Petersen B; Qiu J; Ye F; Houldsworth J; Eng K; Huang F; Hoffman R
Blood Adv; 2018 Sep; 2(18):2378-2388. PubMed ID: 30242099
[TBL] [Abstract][Full Text] [Related]
3. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
Lu M; Xia L; Li Y; Wang X; Hoffman R
Blood; 2014 Jul; 124(5):771-9. PubMed ID: 24869939
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
Maekawa T; Osawa Y; Izumi T; Nagao S; Takano K; Okada Y; Tachi N; Teramoto M; Kawamura T; Horiuchi T; Saga R; Kato S; Yamamura T; Watanabe J; Kobayashi A; Kobayashi S; Sato K; Hashimoto M; Suzu S; Kimura F
Leukemia; 2017 Dec; 31(12):2709-2716. PubMed ID: 28386106
[TBL] [Abstract][Full Text] [Related]
5. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.
Wang X; Ye F; Tripodi J; Hu CS; Qiu J; Najfeld V; Novak J; Li Y; Rampal R; Hoffman R
Blood; 2014 Nov; 124(19):2987-95. PubMed ID: 25193869
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
Wang X; Zhang W; Tripodi J; Lu M; Xu M; Najfeld V; Li Y; Hoffman R
Blood; 2010 Dec; 116(26):5972-82. PubMed ID: 20858855
[TBL] [Abstract][Full Text] [Related]
7. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis.
Chaligné R; James C; Tonetti C; Besancenot R; Le Couédic JP; Fava F; Mazurier F; Godin I; Maloum K; Larbret F; Lécluse Y; Vainchenker W; Giraudier S
Blood; 2007 Nov; 110(10):3735-43. PubMed ID: 17709604
[TBL] [Abstract][Full Text] [Related]
8. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
9. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.
Wang X; Prakash S; Lu M; Tripodi J; Ye F; Najfeld V; Li Y; Schwartz M; Weinberg R; Roda P; Orazi A; Hoffman R
J Clin Invest; 2012 Nov; 122(11):3888-99. PubMed ID: 23023702
[TBL] [Abstract][Full Text] [Related]
10. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
11. C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients.
Wang X; Cho SY; Hu CS; Chen D; Roboz J; Hoffman R
Exp Hematol; 2015 Feb; 43(2):100-9.e1. PubMed ID: 25461253
[TBL] [Abstract][Full Text] [Related]
12. Distinct profile of CD34
Forte D; Barone M; Morsiani C; Simonetti G; Fabbri F; Bruno S; Bandini E; Sollazzo D; Collura S; Deregibus MC; Auteri G; Ottaviani E; Vianelli N; Camussi G; Franceschi C; Capri M; Palandri F; Cavo M; Catani L
J Exp Clin Cancer Res; 2021 Feb; 40(1):49. PubMed ID: 33522952
[TBL] [Abstract][Full Text] [Related]
13. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
14. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.
Zhang Y; Lin CHS; Kaushansky K; Zhan H
Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133
[TBL] [Abstract][Full Text] [Related]
15. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.
Yang Y; Akada H; Nath D; Hutchison RE; Mohi G
Blood; 2016 Jun; 127(26):3410-23. PubMed ID: 27081096
[TBL] [Abstract][Full Text] [Related]
16. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human c-Mpl ligand (thrombopoietin) not only acts on megakaryocyte progenitors, but also on erythroid and multipotential progenitors in vitro.
Tanimukai S; Kimura T; Sakabe H; Ohmizono Y; Kato T; Miyazaki H; Yamagishi H; Sonoda Y
Exp Hematol; 1997 Sep; 25(10):1025-33. PubMed ID: 9293899
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo expansion of human hematopoietic stem cells by a small-molecule agonist of c-MPL.
Nishino T; Miyaji K; Ishiwata N; Arai K; Yui M; Asai Y; Nakauchi H; Iwama A
Exp Hematol; 2009 Nov; 37(11):1364-1377.e4. PubMed ID: 19744539
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ALK5 inhibition in myelofibrosis.
Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
[TBL] [Abstract][Full Text] [Related]
20. Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis.
Bianchi E; Ruberti S; Rontauroli S; Guglielmelli P; Salati S; Rossi C; Zini R; Tagliafico E; Vannucchi AM; Manfredini R
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
